Teleflex Incorporated
HealthcareNYSE:TFX · New York Stock Exchange
+$1.42 today
Vol 0.27M · Avg 0.82M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-29.0%
avg 6.0%
ROIC
4.1%
avg 6.0%
ROA
-13.0%
avg 3.2%
Analysis
ROIC is currently the strongest return metric at 4.1% versus its period average of 6.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John R. Deren | Executive Vice President & Chief Financial Officer | $824,600.00 | — | 58 | $53,983.00 | 0.12% |
Daniel V. Logue | Corporate Vice President, General Counsel & Secretary | $694,888.00 | — | 52 | $24,652.89 | 0.06% |
Cameron Hicks | Corporate Vice President of Human Resources & Communications | $664,042.00 | — | 61 | $19,362.66 | 0.04% |
Stuart A. Randle | CEO, Interim President & Director | $113,500.00 | — | 66 | $16,524.00 | 0.04% |
Greg Stotts | President & GM of Teleflex Medical OEM | — | — | — | — | — |
Praneet Mehrotra | President of APAC | — | — | — | — | — |
Howard Cyr | Corporate Vice President & Chief Compliance Officer | — | — | — | — | — |
Jake Newman | President & GM of Vascular and Emergency Medicine | — | — | — | — | — |
James Ferguson | President & GM of Surgical | — | — | — | $17,760.00 | 0.04% |
Kevin Robinson | President & GM of Anesthesia and Emergency Medicine | — | — | — | — | — |
Lawrence Soren Keusch | Vice President of Investor Relations & Strategy Development | — | — | — | — | — |
Matthew James | President & GM of Interventional | — | — | — | $17,760.00 | 0.04% |
Matt Tomkin | Vice President of Corporate Development | — | — | — | — | — |
Timothy F. Duffy | Vice President & Chief Information Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$633,590.00
Sells
0
$0.00
Net Sentiment
+$633,590.00
Net buying
Most Active
HAGGERTY GRETCHEN R
2 transactions
Analysis
Insiders reported 6 buys worth $633,590.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $633,590.00. HAGGERTY GRETCHEN R was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +6.6% (15yr)1 analysts |
| Revenue | N/A | N/A | +5.3% | +3.0% (15yr)7 analysts |
| Net Income | N/A | N/A | N/A | +6.1% (15yr)7 analysts |
| EBIT | N/A | N/A | N/A | +1.4% (15yr)7 analysts |
Analysis
Recent growth has been strongest in Revenue at +5.3% over three years. Forward estimates point to EPS at +6.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.45B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.38B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.57B
Alkermes plc
NASDAQ:ALKS
$7.42B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.87B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
Bausch + Lomb Corporation
NYSE:BLCO
$5.38B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.81B
Stevanato Group S.p.A.
NYSE:STVN
$4.66B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.97B
Who manages TFX?
Teleflex Incorporated (TFX) lists 14 active executives. The top listed executive is Cameron Hicks, Corporate Vice President of Human Resources & Communications.
Are TFX insiders buying or selling?
Recent insider activity shows net buying of $43.28M.
Explore More
Continue the stock analysis
Jump to another research area for this company.